 |
인쇄하기
취소
|
Will Hanmi Pharm start to develop modified drug of ‘Evista’?
Hanmi Pharm is about to jump in the development of incrementally modified drug of Evista(generic name: raloxifene), an osteoporosis therapy.
Hanmi Pharm was confirmed to file a defensive confirmation trial for the scope of the ‘Drugs Containing Benzothiophene and Methods’(March 20, 2017) patent on the 30th last month.
When it comes to Hanmi Pharm which already applied for the preferential tri...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.